MiMedx Group (NASDAQ:MDXG) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of MiMedx Group (NASDAQ:MDXG) from a buy rating to a strong-buy rating in a research report sent to investors on Friday.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th.

MiMedx Group Trading Down 3.4 %

Shares of MiMedx Group stock opened at $7.06 on Friday. The company’s 50-day moving average price is $8.11 and its 200-day moving average price is $7.94. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a market cap of $1.04 billion, a price-to-earnings ratio of 12.84 and a beta of 1.74.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.07. The business had revenue of $92.91 million for the quarter, compared to analysts’ expectations of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. On average, equities analysts expect that MiMedx Group will post 0.3 earnings per share for the current fiscal year.

Insider Transactions at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 4,106 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the sale, the insider now owns 310,836 shares in the company, valued at $2,452,496.04. The trade was a 1.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO William Frank Iv Hulse sold 81,446 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $7.80, for a total value of $635,278.80. Following the completion of the sale, the chief accounting officer now directly owns 494,774 shares of the company’s stock, valued at approximately $3,859,237.20. This represents a 14.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 144,018 shares of company stock valued at $1,130,312 in the last quarter. Insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On MiMedx Group

Hedge funds have recently made changes to their positions in the business. Invesco Ltd. raised its position in MiMedx Group by 2.2% in the 4th quarter. Invesco Ltd. now owns 56,565 shares of the company’s stock worth $544,000 after purchasing an additional 1,226 shares during the period. Disciplined Growth Investors Inc. MN boosted its holdings in MiMedx Group by 0.8% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company’s stock valued at $2,100,000 after acquiring an additional 2,737 shares during the period. Tower Research Capital LLC TRC grew its position in MiMedx Group by 77.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock worth $63,000 after acquiring an additional 2,837 shares during the last quarter. IMG Wealth Management Inc. purchased a new position in MiMedx Group in the 4th quarter worth approximately $28,000. Finally, SkyView Investment Advisors LLC lifted its position in MiMedx Group by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock valued at $77,000 after purchasing an additional 3,000 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.